BRCA2 (human) AlphaLISA Detection Kit, 5,000 assay points

The AlphaLISA® immunoassay kit for human breast cancer type 2 susceptibility protein (BRCA2) enables the quantitative determination of human BRCA2 in serum, buffered solution, and cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps)..Formats: Our 100 assay point kit allows you to run 100 wells in 96-well format, using a 100 µL reaction volume (10 µL of sample). Our 500 assay point kit allows you to run 500 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Our 5,000 assay point kit allows you to run 5,000 wells in 96-well or 384-well format, using a 50 µL reaction volume (5 µL of sample). Features: No-wash steps, no separation steps ELISA alternative technology Sensitive detection Broad sample compatibility Small sample volume Results in less than 3 hours Half the time of an ELISA assay AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm. BRCA2, known as breast cancer 2 or breast cancer type 2 susceptibility protein, is expressed in breast tissue cells and other reproductive tissues. It primarily functions to sense and repair DNA damage or destroy cells if DNA cannot be repaired. Inherited mutation of BRCA2 accounts for many cases of familial breast and ovarian cancer. Mutations in BRCA2 can also lead to an increased risk of prostate and pancreatic cancers, as well as malignant melanoma.